medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 4

<< Back Next >>

Ann Hepatol 2013; 12 (4)

Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients

Janicko M, Veselíny E, Leško D, Jarcuška P

Language: English
References: 16
Page: 413-419
PDF size: 114.12 Kb.


ABSTRACT

Background and Aim. Accurate assessment of cirrhotic patient’s prognosis is essential for decisions regarding the course of treatment. Therefore we aimed to confirm and quantify the predictive value of serum cholesterol and serum triglycerides in liver cirrhosis patients. Material and methods. We performed a retrospective observational cohort study on consecutive patients with liver cirrhosis (n = 191). Relevant clinical and laboratory variables were obtained from patients‘ charts and patients were followed for two months. Mortality was the main outcome. Results. Thirty-eight patients died in the follow-up period. Significant difference was observed in the level of total serum cholesterol between surviving and deceased patients (2.27 ± 1.02 mmol/L vs. 2.97 ± 1.00 mmol/L, P ‹ 0.0001 respectively). Cholesterol was confirmed as a significant predictor of mortality in univariate logistic regression analysis, and independent predictor beside bilirubin, creatinine and MELD score in multivariate logistic regression analysis. Addition of serum cholesterol level to a prognostic model based on total bilirubin, creatinine and INR increased its accuracy by 4%. Adding cholesterol to the MELD score improved prediction accuracy by 3%. There was no significant difference in serum levels of triglycerides between surviving and deceased patients. Conclusion. Serum cholesterol is a routinely measured parameter, which has independent prognostic value in patients with liver cirrhosis.


REFERENCES

  1. Krahenbuhl L, Lang C, Ludes S, Seiler C, Schafer M, Zimmermann A, Krahenbuhl S. Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int 2003; 23: 101-9.

  2. Vogt J. Gluconeogenesis in patients with impaired liver function. Zeitschrift fur Ernahrungswissenschaft 1997; 36: 364-7.

  3. Wang TY, Newby LK, Chen AY. Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. Clinical Cardiology 2009; 32: E22-E28.

  4. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

  5. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Archives of internal medicine. 1997; 157: 792-6.

  6. Llovet JM, Planas R, Morillas R, Quer JC, Cabre E, Boix J, Humbert P, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993; 88: 388-92.

  7. Milani A, Marra L, Siciliano M, Rossi L. Prognostic significance of clinical and laboratory parameters in liver cirrhosis. A multivariate statistical approach. Hepato-gastroenterology 1985; 32: 270-2.

  8. D’Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 1998; 33: 1213-8.

  9. Jiang M, Liu F, Xiong WJ. Combined MELD and blood lipid level in evaluating the prognosis of decompensated cirrhosis. World J Gastroenterol 2010; 16: 1397-401.

  10. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Experimental physiology 2008; 93: 27-42.

  11. Davidson M, Jacobson TA. How Statins Work: The Development of Cardiovascular Disease and Its Treatment With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Medscape. (Serial online) 2001 13.4.2011. (Cited 13.4.2011). Available from: http://www.medscape.org/ viewprogram/608

  12. Malmendier CL, Delcroix C, Lontie JF. Kinetics of a heterogeneous population of particles in low density lipoprotein apolipoprotein B. Atherosclerosis 1989; 80: 91-100.

  13. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.

  14. Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Physicians India 2001; 49: 274-8.

  15. Habib A, Mihas AA, Abou-Assi SG. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol 2005; 3: 286-91.

  16. Fernández Pérez FJ, Pallarés Manrique H, Cabello Ramírez M. Zieve’s syndrome. A case report. Rev Esp Enferm Dig 1996; 3: 226-9.




2020     |     www.medigraphic.com